Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18152876 | 0.90 | BRD4 (0.50) | BRD4 | |
| SCHEMBL23073001 | 0.87 | BRD4 (0.43) | BRD4GRIN1GRIN2BP2RX7MAPT | |
| SCHEMBL23473033 | 0.86 | BRD4 (0.44) | BRD4GRIN1GRIN2BP2RX7 | |
| SCHEMBL18538434 | 0.86 | BRD4 (0.46) | BRD4GRIN1GRIN2B | |
| SCHEMBL18164153 | 0.85 | BRD4 (0.46) | BRD4 | |
| SCHEMBL18152773 | 0.84 | BRD4 (0.48) | BRD4MAPT | |
| SCHEMBL18164472 | 0.84 | BRD4 (0.46) | BRD4MAPT | |
| Hydrochloric Acid SCHEMBL18152835 | 0.83 | BRD4 (0.47) | BRD4MAPT | |
| SCHEMBL18538405 | 0.82 | BRD4 (0.59) | BRD4 | |
| SCHEMBL18541952 | 0.82 | BRD4 (0.51) | BRD4GRIN1GRIN2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3283077-A2 | BROMODOMAIN INHIBITOR | Celgene Quanticel Research, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016168682-A2 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885GRIN1 1750/4885GRIN2B 2871/4885 |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | BRD3, BRPF3, EP300 | BRD4 5/4885GRIN1 1760/4885GRIN2B 2863/4885 |
| US-10807982-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885GRIN1 1750/4885GRIN2B 2871/4885 |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885GRIN1 1750/4885GRIN2B 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.